Details
- Titel
- BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
- Ist Teil von
- Business Wire, 2024
- Ort / Verlag
- New York: Business Wire
- Erscheinungsjahr
- 2024
- Sprache
- Englisch
- Identifikatoren
- Titel-ID: cdi_proquest_wirefeeds_3061272199
- Format
- –
- Schlagworte
- Autoimmune diseases, Blood, Cancer, Coronary vessels, Endocrine disorders, FDA approval, Heart attacks, Hypertension, Inflammatory bowel disease, Interferon, Ischemia, Mental disorders, Oncology, Pancreatitis, Patients, Phlebotomy, Physicians, Suicidal behavior, Suicides & suicide attempts, Thrombosis, Thyroid gland, Toxicity, Tumors, Veins & arteries